ADVANCED DRUG DELIVERY SYSTEM

Abstract

Controlled drug delivery systems have emerged as a promising approach to enhance therapeutic efficacy, reduce dosing frequency, and improve patient compliance in medical treatments. These systems offer the advantage of maintaining drug levels within the desired therapeutic range, optimizing drug utilization, and providing sustained drug release. However, along with these benefits, potential challenges must be addressed to ensure their successful implementation in clinical practice.

This review explores the advantages and disadvantages of controlled drug delivery systems. The benefits of controlled drug delivery include maintaining drug concentrations at optimal levels, minimizing dosing frequency, and improving patient adherence to treatment regimens. These advantages can lead to more effective and convenient therapies for chronic conditions.

On the other hand, certain limitations need to be considered. The materials used in the delivery system may present concerns related to toxicity and biocompatibility. The degradation of the drug may generate undesirable by-products. Surgical procedures might be required for the implantation or removal of the delivery device, potentially leading to patient discomfort. Additionally, the cost of controlled-release systems can be higher than conventional pharmaceutical formulations.

The ideal drug delivery system should meet several key criteria, such as biocompatibility, mechanical strength, patient comfort, high drug loading capacity, safety against accidental release, ease of administration and removal, and simple fabrication and sterilization processes.

Author

Indu Kanaujia
Assistant Professor
Institute of Pharmaceutical Sciences & Research
Unnao, Uttar Pradesh, India.
indukanaujia13@gmail.com

Despite these challenges, advancements in materials science and pharmaceutical technology hold great potential for developing more effective and patient-friendly controlled drug delivery systems. By striking a careful balance between advantages and challenges, these innovative systems offer a promising path towards improving therapeutic outcomes and patient well-being across a wide range of medical conditions. Further research and development in this field are essential to realize the full potential of controlled drug delivery systems in clinical settings.

Keywords: Drug Delivery, therapeutic, mechanical strength, GI.

I. INTRODUCTION

Drug delivery via oral administration is a complex process that involves overcoming challenges such as withstanding digestive processes and crossing the gastrointestinal (GI) barrier to enter the bloodstream. The oral route is commonly preferred for systemic drug delivery, despite its disadvantages like unpredictable and erratic absorption, gastrointestinal intolerance, incomplete absorption, drug degradation in GI contents, and presystemic metabolism, leading to reduced bioavailability [1].

The GI tract serves vital functions like food absorption, digestion, and secretion of enzymes and fluids [2]. It acts as a protective barrier between the body and the luminal environment, which may contain harmful microorganisms and toxins. Maintaining the normal function of the GI barrier is crucial for disease prevention and overall health. The main challenge in drug delivery through the GI tract is to achieve efficient transport of nutrients and drugs while preventing the entry of harmful substances into the body.

To enhance drug delivery, advanced systems are being developed to target specific sites and release drugs in a controlled manner. These advancements aim to improve the effectiveness of existing drugs by delivering them at a controlled rate and ensuring targeted absorption and release at the desired location.

II. IMPORTANCE OF ADVANCED DRUG DELIVERY SYSTEMS

Advanced drug delivery systems (DDS) offer undeniable advantages in drug administration. Over the last thirty years, innovative approaches have been proposed to develop new carriers for drug delivery. In this review, we discuss general concepts and emerging research in this field, emphasizing multidisciplinary approaches that aim to provide personalized treatments for a wide range of prevalent diseases like cancer and diabetes. The review is divided into two parts.

The first part provides an overview of currently available drug delivery technologies, tracing their development history and highlighting various research strategies employed. It explores the advancements that have been made and the existing systems in use.

The second part focuses on the most advanced drug delivery devices that utilize stimuli-responsive polymers. These polymers are synthesized using a controlled-living radical polymerization strategy, allowing for precise and tailored drug release responses. The potential of these systems is promising, with the likelihood of witnessing the emergence of new and effective custom-made DDS in the future. This progress will be driven by the integration of knowledge from different interdisciplinary sciences, all contributing to the creation of personalized medical solutions.

III. THE PURPOSE OF THE PAPER

Drug delivery involves the administration of pharmaceutical compounds to achieve therapeutic effects in humans or animals. Nasal and pulmonary routes of drug delivery are becoming increasingly important for the treatment of human diseases. These routes offer promising alternatives to traditional parenteral drug delivery, especially for peptide and protein-based therapies. To facilitate nasal and pulmonary delivery, various drug delivery systems have been developed and are under investigation.

Some of these delivery systems include liposomes, pro liposomes, microspheres, gels, prodrugs, and cyclodextrins, among others. Among the most promising options are nanoparticles made from biodegradable polymers. These nanoparticles demonstrate the potential to meet the stringent requirements placed on such delivery systems. These requirements include the ability to form an aerosol, stability against forces generated during aerosolization, biocompatibility, targeted delivery to specific sites or cell populations in the lungs, controlled release of the drug, and degradation within an acceptable timeframe.

The development of these advanced drug delivery systems holds great promise for enhancing the effectiveness and safety of drug therapies delivered through the nasal and pulmonary routes, particularly for complex therapeutics like peptides and proteins.

IV. OVERVIEW OF MICRONEEDLES

1. **Definition**: Microneedles (MNs) are tiny needles, ranging in height from 25 to 2000 micrometers, and they come in various materials and shapes. When applied to the skin, MNs create micro-sized pathways that enable improved delivery of various drug molecules.

   The idea of microneedles was initially introduced in 1970. These needles offer a unique combination of advantages, blending the benefits of hypodermic needle injections and transdermal patches.

   Typically, microneedles are hundreds of microns in length, with the tip measuring 1 to 50 micrometers wide and the base approximately 50 to 300 micrometers wide. This design allows for controlled and targeted drug delivery through the skin, providing a promising approach for enhancing the efficiency and convenience of drug administration.

2. **Characteristics of microneedles**:Microneedles are indeed considered a novel and smart injection system designed to minimize skin invasion during the puncturing process. Their micron-sized dimensions enable painless penetration into the skin.

   The primary goal of microneedles is to create microscopic pathways through the skin using an array of tiny needles attached to a metal or polymer base. These pathways allow for enhanced drug delivery, offering a less invasive and more patient-friendly alternative to traditional hypodermic needle injections. By exploiting these microscopic channels, microneedles can effectively deliver drugs and other therapeutic substances with improved efficiency and precision. This innovative approach holds great promise for various medical applications, including vaccination, local anesthesia, and the treatment of various medical conditions.

3. **Types of Microneedles:** The various types of microneedles mentioned in the description offer distinct advantages and applications in drug delivery and medical treatments. Here is a brief overview of each type:

   - **Solid Microneedles:** These microneedles create microscopic wells in the skin, just deep enough to penetrate the outermost layer. They are often used in combination with transdermal patches for drug delivery and have applications in dermatology for collagen induction therapy.

- **Hollow Microneedles:** Similar in material to solid microneedles, hollow microneedles contain reservoirs to directly deliver drugs to the site. However, the drug delivery in this type depends on the flow rate of the microneedle, which could be affected by potential clogging or design flaws, making it less practical in some cases.

- **Coated Microneedles:** Coated microneedles have drugs directly applied to their surface. They are made from polymers or metals and may be coated with other agents to ensure proper drug delivery. However, there is a risk of local inflammation due to the chemicals used in the coating.

- **Dissolvable Microneedles:** A recent adaptation, dissolvable microneedles encapsulate drugs in a nontoxic polymer that dissolves inside the skin. These microneedles allow for drug delivery into the skin and subsequent breakdown within the body, offering a more convenient and patient-friendly option.

- **Hydrogel Forming Microneedles:** Medications are enclosed in a polymer with hydrogel-forming microneedles. The microneedles can penetrate the outermost skin layer and draw up interstitial fluid, leading to swelling of the polymer, through which drugs can be delivered into the skin.

These diverse microneedle types provide versatile options for drug delivery, offering potential solutions to various medical challenges while reducing the discomfort and invasiveness associated with traditional injection methods. As research and development continue, microneedles hold great promise in revolutionizing drug delivery and medical treatments.

4. **Advantages:** Microneedles offer numerous advantages that make them a promising alternative to traditional hypodermic needles for drug delivery and medical procedures:

- **Improved Comfort for Patients:** Microneedles are less painful and can significantly reduce anxiety and fear associated with needle phobia in both adults and children. Patients, especially children, may be more willing to undergo blood sampling or drug administration with microneedles due to the reduced pain and discomfort.

- **Reduced Hazardous Waste:** Microneedles produce less hazardous waste compared to traditional needles, making disposal easier and safer for healthcare professionals. This is particularly beneficial for home-based healthcare, where proper disposal of used needles can be challenging.

- **Cost-Effectiveness:** Microneedles require less material than traditional needles, making them less expensive to produce. The materials used in microneedles are generally more affordable than those used in hypodermic needles.

- **Home and Community-Based Healthcare**: Microneedles, especially dissolvable or swelling ones, present an opportunity for patients to safely self-administer medication at home, reducing the need for frequent hospital visits. This is especially beneficial for patients with limited mobility or accessibility to medical facilities.

- **Lower Rates of Microbial Invasion:** Microneedles cause smaller puncture wounds in the skin, reducing the risk of bacterial entry compared to traditional injections. The shallow puncture site makes it more challenging for harmful bacteria to enter the bloodstream, potentially lowering the risk of infection.

While microneedles show significant promise, further research is needed to fully understand their potential and address any remaining concerns, such as disposal of solid or hollow microneedles and potential bacterial breaches at the puncture site. Nonetheless, their numerous benefits make them a compelling avenue for advancing drug delivery and medical procedures in the future.

5. **Disadvantages:** There are valid concerns regarding the proper application and effectiveness of microneedles in drug delivery. Physicians need to be adequately trained in the correct application of microneedle arrays to ensure that all the drug or vaccine enters the skin for optimal effectiveness.

- Hollow and coated microneedles indeed carry a risk of drug leakage if damaged or incorrectly applied. Ensuring proper handling and application is crucial to prevent any potential drug wastage and ensure the desired therapeutic outcome.
- Additionally, the fragility of microneedles is a concern, as they may break off and remain in the skin, leaving foreign materials behind. Some microneedle materials, such as titanium, cannot be absorbed by the body, leading to potential irritation and other adverse effects if fragments remain in the skin.
- Despite the promising potential of microneedle drug delivery, there is still limited literature available on the subject. Ongoing research is focused on optimizing the design, fabrication, and application of microneedles to ensure their efficacy and safety.
- Addressing these concerns through further research and training will be crucial in harnessing the full potential of microneedles as an advanced and patient-friendly drug delivery system. As the technology continues to evolve, microneedles hold great promise in revolutionizing drug delivery and medical treatments.

V. APPLICATION OF MICRONEEDLES IN DRUG DELIVERY

1. **Transdermal drug delivery:** Transdermal drug delivery systems offer numerous advantages compared to traditional administration routes like intravenous or oral methods. These systems allow drug absorption through the skin, providing both systemic and local drug delivery with straightforward administration.

A transdermal drug delivery system, also known as a transdermal patch or skin patch, delivers a specific dose of medication directly into the systemic circulation. The patch is designed as a medicated adhesive patch that adheres to the skin and gradually releases the drug.

When delivering therapeutic agents through the skin for systemic effects, it is essential to consider the morphological, biophysical, and physicochemical properties of the skin (Patel and Kavitha, 2011).

The transdermal patch of scopolamine was the first FDA-approved transdermal patch in 1981. It is used for the prevention of motion sickness (Transdermic, ALZA Corp.), and there are other patches like nitro-glycerine for preventing angina pectoris associated with coronary artery disease (Transdermal Nitro).

Transdermal patches eliminate the need for syringe-based vascular access or the use of pumps. Today, there are various patches available for delivering drugs such as clonidine, fentanyl, lidocaine, nicotine, nitro-glycerine, oestradiol, oxybutynin, scopolamine, and testosterone. Combination patches are also used for contraception and hormone replacement therapy. Depending on the drug, these patches typically last from one to seven days.

Overall, transdermal drug delivery systems are designed to deliver a therapeutically effective dose of a drug through the patient's skin at a controlled rate for systemic effects, offering convenience, steady drug release, and patient comfort.

Table 1: Some marketed Transdermal Products.

Product	Drug	Manufacturer	Indication
Alora	Estradiol	Thera Tech/ Porctol and Gamble	Postmenstrual syndrome
Androderm	testosterone	Theratech/ GalxosmithKline	Hypogonadism in males
Catapres-TTS	clonidine	ALZA/Boehinger Ingelheim	Hypertension
Climaderm	Estradiol	EthicalHoldings/Wyeth-Ayerest	Postmenstrual syndrome

2. **Vaccine delivery system:** Vaccines are essential preparations given to patients to trigger immune responses that produce antibodies or cell-mediated responses to combat infectious agents or non-infectious conditions like malignancies. However, some challenges with existing vaccine types, such as live vaccines' safety profile, sub-unit vaccines' weak immunogenicity, and poor patient compliance to booster doses, have highlighted the need for new generations of prophylactic and therapeutic vaccines to enhance immunization effectiveness.

   To address these issues, efforts are being made to deliver vaccines through carrier systems, which can control the presentation of antigens to the immune system in a spatial and temporal manner, leading to sustained release and targeted delivery. By using these carriers, lower doses of weak immunogens can effectively stimulate immune responses, eliminating the need for traditional prime and booster doses in vaccination regimens.

This paper reviews various carrier systems, including liposomes, microspheres, nanoparticles, dendrimers, micellar systems, ISCOMs (immune-stimulating complexes), and plant-derived viruses, which are being investigated and developed as vaccine delivery systems. These carriers show promise in improving vaccine efficacy and overcoming some of the limitations associated with conventional vaccines.

Additionally, the paper describes different aspects of "needle-free technologies" used to administer vaccine delivery systems through various routes into the human body. These needle-free methods offer potential advantages in terms of improved patient compliance, reduced pain, and the potential for broader vaccine coverage in populations.

The development of novel vaccine delivery systems, combined with needle-free technologies, holds the potential to revolutionize vaccination strategies, leading to more effective immunization and enhanced protection against infectious diseases and other health conditions.

3. **Localised drug delivery:** Local drug delivery systems play a crucial role in delivering a minimal amount of drug directly to affected tissues over a specific period, thereby minimizing off-target side effects and improving patient compliance. These systems are particularly valuable for conditions that require long-term medication, such as chronic inflammation. By attenuating metabolism or clearance, reducing administration frequency, and targeting specific tissues, local drug delivery systems offer advantages in managing inflammatory diseases.

   Over the years, numerous local drug delivery systems have been developed and introduced to treat inflammatory diseases. These products and experimental approaches showcase the advancements in biomaterials and drug delivery technology and demonstrate the complexity of these diseases.

   The primary objective of this article is to review the various local drug delivery products utilized in the therapy of chronic inflammatory diseases and assess their current status. As the literature is collected and analyzed, it becomes evident that several challenges persist, despite technical advances in drug delivery. In some applications, the potential of local drug delivery technology remains underutilized.

   The review article aims to shed light on local drug delivery systems targeting various inflammatory diseases, including well-known targets such as joints, eyes, and teeth, as well as other untapped opportunities like sinus, bladder, and colon. The article discusses the current status, challenges, and future directions in the field.
   By exploring and understanding the strengths and limitations of existing local drug delivery systems, this review seeks to pave the way for further advancements and applications in the management of chronic inflammatory diseases. The hope is that future developments will enhance patient outcomes, improve disease management, and contribute to the broader field of drug delivery science.

4. **Uveitis:** Uveitis is an inflammation of the uveal tract of the eye, comprising the iris, ciliary body, and choroid. It is clinically referred to as inflammations affecting all parts of the eye, including the anterior, middle, and posterior segments. Uveitis is categorized into

three types based on the site of inflammation. Anterior uveitis involves inflammation of the iris (iritis) and anterior ciliary body (anterior cyclitis).

On the other hand, periodontal diseases (PD) are a group of destructive inflammatory diseases affecting the periodontal tissues, which include gingivitis and periodontitis. These conditions have adverse effects on oral functions and overall quality of life. PD begins with inflammation of the gingival tissues and progresses to the formation of pockets, providing a favorable environment for the growth of anaerobic microorganisms. This leads to bone loss, tooth mobility, and potential tooth loss. While mechanical approaches are the primary treatment for PD, local or systemic interventions may be necessary to manage the inflammation and prevent disease progression.

5. **Combination therapies:** Combination therapy, also known as polytherapy, involves using more than one medication or treatment modality to address a single disease or condition. This approach is commonly used in medicine and can include various combinations of pharmaceutical drugs or a combination of medical and non-medical therapies.

   Pharmaceutical combination therapy may involve prescribing or administering separate drugs or using dosage forms that contain multiple active ingredients, known as fixed-dose combinations. This approach is widely used in treating various conditions, including tuberculosis, leprosy, cancer, malaria, and HIV/AIDS.

   One significant advantage of combination therapies is their ability to reduce the development of drug resistance. When multiple drugs are used simultaneously, it becomes less likely for pathogens or tumors to develop resistance to all of them at the same time. This is particularly important in diseases like malaria, where artemisinin-based monotherapies are discouraged to prevent resistance from emerging.

   Although combination therapy may appear costlier than monotherapy in the short term, it often leads to significant long-term savings. This is because it can result in lower treatment failure rates, reduced hospitalizations, and better overall disease management, ultimately leading to improved patient outcomes and reduced healthcare costs. Overall, combination therapy is a valuable approach in modern medicine, offering enhanced effectiveness and minimizing the development of drug resistance in the treatment of various diseases. rate, lower case-fatality ratios, fewer side effects than monotherapy, a slower development of resistance, and thus less money needed for the development of new drug

VI. IMPLANTABLE DRUG DELIVERY SYSTEMS

1. **Introduction:** The oral route of drug administration is the most common method, accounting for about 90% of drug delivery. However, this route has its challenges, such as unpredictable plasma concentrations, degradation of drugs in the acidic stomach environment, irritation of the gastrointestinal tract, and first-order metabolism leading to reduced drug concentrations in the bloodstream. These issues often make it difficult or impractical to administer certain drugs orally.

To address these drawbacks, researchers worldwide are actively exploring novel drug delivery systems that offer controlled and sustained release of drugs at both the plasma level and the target site where the action is required. The goal is to overcome the limitations of traditional drug delivery methods.

Implantable drug delivery systems have gained popularity since 1938 when Deansby and Parkes implanted a compressed pellet subcutaneously. These systems involve surgically inserting an implant into the body, which allows for targeted drug delivery and maximizes the drug's beneficial effects while minimizing the risk of life-threatening conditions.

Implantable drug delivery systems have demonstrated effectiveness in cases where oral administration is not feasible or less bioavailable, such as certain antibiotics, NSAIDs, contraceptives, etc. These systems offer a strong solution for delivering medications to a large population of people and animals who could benefit significantly from such devices.

In addition to implantable drug delivery, other drug delivery systems have been developed, but their broad-scale application has been limited due to various medical requirements. Nevertheless, drug delivery systems, particularly implantable ones, have been successful in providing consistent and precise drug dosing over extended periods, improving treatment responses and local drug concentrations for specific conditions like chemotherapy. As research and technology continue to advance, novel drug delivery systems hold great promise for enhancing therapeutic outcomes and patient care.

2. The ideal requirements of implantable drug delivery systems include:

- **Environmentally stable:** The system should be able to withstand the physiological environment within the body without degradation.
- **Biocompatible:** The materials used in the implant should be compatible with the body's tissues to minimize adverse reactions or immune responses.
- **Sterile:** The implant must be free from any contaminants to prevent infections.
- **Biostable:** The implant should maintain its structural integrity and drug release characteristics over the intended duration of treatment.
- **Improve patient compliance:** The system should reduce the frequency of drug administration, making it more convenient for patients to adhere to the treatment plan.
- **Rate-controlled drug release:** The implant should release the drug in a controlled manner to enhance its effectiveness and reduce side effects.
- **Readily retrievable:** Medical personnel should be able to remove the implant when the treatment is complete or if necessary due to adverse reactions.
- **Easy to manufacture and relatively inexpensive:** The manufacturing process should be practical and cost-effective.

3. The benefits of an implantable drug delivery system include:

- **Improved efficiency:** The controlled and continuous release of the drug leads to improved therapeutic outcomes.

- **Higher effectiveness:** A small dose of the drug delivered directly to the target site can produce the desired action.
- **Reduced side effects:** The controlled release can minimize systemic exposure and associated side effects.
- **On-spot delivery:** The drug is delivered precisely to the required location, avoiding the need for repeated administration.
- **Convenient therapy:** Patients experience reduced dosing frequency, resulting in enhanced convenience.
- **Prolonged linear delivery:** Implants can maintain therapeutic drug levels for an extended period, ranging from weeks to months.
- **Continuous maintenance of drug levels:** Plasma drug levels are kept within a desirable range for effective treatment.

4. Limitations of implantable drug delivery systems include:

- **Possible toxicity:** The release of high drug concentrations at the implantation site may lead to local toxicity.
- **Need for microsurgery:** Implantation requires a surgical procedure, which can be challenging and carries some risks.
- **Possible pain:** Patients may experience discomfort or pain during and after the implantation procedure.
- **Difficulty in stopping drug release:** Terminating drug delivery can be complex, especially with non-biodegradable implants.

VII. IMPLANTABLE PUMP SYSTEMS

Advancements in drug delivery technology have led to the development of implantable pump systems that offer external control over drug delivery rate and volume. Unlike biodegradable or nondegradable delivery systems, implantable pump systems, including magnetic-type delivery systems, provide the necessary control for drugs that require precise regulation.

With the availability of advanced microtechnology, it is now possible to create small pump systems that can be implanted subcutaneously to deliver drugs. This allows patients to have direct control over drug release without the need for an external pump system, enhancing convenience and patient autonomy.

One notable example of the application of implantable pump systems is in the control of type 1 diabetes, where insulin pump systems have been successfully utilized. These pump systems differ from other implantable drug delivery systems in their mechanism of drug release. They rely on pressure difference-generated gradients to facilitate the bulk flow of drugs at controllable rates.

Several types of implantable pump systems have been tested to date, including infusion pumps, peristaltic pumps, osmotic pumps, positive displacement pumps, and controlled release micropump systems. Each type offers unique advantages and may be suitable for specific drug delivery requirements.

Overall, implantable pump systems represent a significant advancement in drug delivery technology, providing patients with greater control over drug administration and improving the management of various medical conditions.



Figure 1: Schematic of an insulin implantable pump

VIII. OSMOTIC PUMPS

Osmotic pumps have emerged as the most popular type of implantable drug delivery system. Also known as Oros or gastrointestinal therapeutic systems, osmotic pumps were first described by Theeuwes and Yum and later released for use by Alza Corporation.

The design of osmotic pumps involves a drug reservoir surrounded by a semipermeable membrane. The semipermeable membrane allows a continuous influx of water and biological fluid into the reservoir through osmosis. This influx creates hydrostatic pressure, resulting in a steady and controlled release of the drug through a drug portal in the membrane. The rate of drug release remains constant or zero-order until the drug reservoir is fully depleted.

One of the significant advantages of osmotic pump systems is that they avoid the "initial burst effect" commonly observed in other degradable or nondegradable matrix systems. This effect refers to a rapid release of a large amount of drug upon administration, which may lead to suboptimal dosing and potential side effects. In osmotic pump systems, the release of drugs occurs at a controlled and consistent rate, promoting stable plasma concentrations over an extended period.

Clinical applications of osmotic pump systems have demonstrated their effectiveness in pain management. For instance, osmotic pumps containing hydromorphone have been subcutaneously implanted to manage chronic pain. Studies have shown that these pumps release hydromorphone at a constant rate, leading to stable plasma concentrations over a two-week period.

Due to their controlled drug release and ability to maintain stable drug levels, osmotic pump systems hold great promise for the treatment and management of various chronic conditions. As a result, it is likely that such systems will be used more extensively in the future to improve patient outcomes and enhance drug delivery efficiency.

IX. POSITIVE DISPLACEMENT PUMPS

Positive displacement pumps have been developed for continuous insulin delivery in diabetic patients. These pumps utilize piezoelectric disc benders that are attached to flexible tubing. To create the pump, the piezoelectric discs are first exposed to specific voltages, causing them to form spherical surfaces. The bellow-type system is then connected to a drug reservoir through a three-way solenoid-driven valve.

When the pump is exposed to electrical pulses, the valves open or close based on the direction of the pulse. This action controls the release of insulin from the drug reservoir, enabling precise and continuous delivery at the desired rate. The rate of insulin release is determined by the frequency and duration of the electrical pulses.

Similar designs using positive displacement pumps are currently being developed for the delivery of insulin, offering a promising solution for diabetic patients who require consistent and controlled insulin administration.

These innovative pump systems provide a potential improvement over traditional insulin administration methods, allowing for better management of blood glucose levels and enhancing overall diabetes care. As research and technology continue to advance, positive displacement pumps are expected to play an increasingly important role in insulin delivery and other drug administration applications..



Figure 2: Cross-sectional view of an implantable peristaltic pump showing all important components

X. ADVANTAGES

1. Advantages of implantation therapy include

- **Convenience:** Implantation therapy allows for prolonged drug concentrations in the bloodstream, reducing the need for frequent hospital visits and medical monitoring compared to continuous intravenous infusion or injections. It also lowers the risk of infection-related complications associated with catheter-based infusion systems.

- **Compliance:** Implantation therapy enhances patient compliance by reducing or eliminating the need for patient-involved dosing. Patients no longer need to remember to take medications as drug delivery from the implant is largely independent of patient input.

- **Potential for controlled release:** Implants can provide drugs through controlled release kinetics, avoiding toxicity and ineffectiveness associated with conventional therapy, reducing dosing frequency, and improving patient compliance.

- **Potential for intermittent release:** Programmable implants can facilitate intermittent drug release, responding to factors like circadian rhythms and fluctuating metabolic needs.

- **Potential for bio-responsive release:** Ongoing research explores the possibility of implants that release drugs based on the body's specific needs.

- **Improved drug delivery:** Implant systems deliver drugs locally or systemically, bypassing biological and metabolic barriers like the gastrointestinal tract and liver, which is particularly beneficial for poorly absorbed or easily inactivated drugs.

- **Flexibility:** Implant systems offer flexibility in material choice, manufacturing methods, drug loading, and release rate, providing opportunities to diversify drug product portfolios.

2. Disadvantages of implantation therapy include

- **Invasive:** Initiating therapy requires a surgical procedure, which can be traumatic and result in surgery-related complications or discomfort for the patient.

- **Termination:** Non-biodegradable implants and osmotic pumps require surgical retrieval after treatment, and biodegradable implants may present challenges in terminating drug delivery.

- **Danger of device failure:** There is a risk that the implant device may fail to operate, requiring surgical intervention for correction.

- **Limited to potent drugs:** Implants have limited loading capacity, restricting their use to potent drugs such as hormones.

- **Possibility of adverse reactions:** The concentrated drug delivery at the implantation site may trigger adverse reactions.
- **Biocompatibility issues:** Concerns about the body's response to foreign materials raise questions about the biocompatibility and safety of implants.

XI. APPLICATIONS OF IMPLANTABLE DRUG DELIVERY SYSTEMS

1. **Long-term drug delivery for chronic conditions:** Chronic diseases, also known as chronic non-communicable diseases, are complex and often incurable conditions that require ongoing medical management. They represent a significant global health burden, accounting for a substantial proportion of all deaths worldwide. In recent years, chronic diseases have become the primary threat to human health, with China experiencing a high percentage of deaths caused by these conditions.

   Targeted drug delivery systems offer a promising approach to tackle chronic diseases more effectively. These systems enable the concentration of the active ingredient of a medicine at the specific site of a lesion or targeted organ, ensuring a longer duration of drug effectiveness. By delivering the drug directly to the intended site, targeted therapy can reduce adverse effects and enhance patient safety. This, in turn, allows patients to receive medications at lower doses, promoting better adherence to prescribed treatment plans.

   Targeted therapy focuses on delivering therapeutic drugs to pathogenic organs or specific sites of action at a cellular or molecular level. The application of targeted agents in pharmacy has seen widespread adoption due to their ability to mitigate drug-related adverse effects and improve patient compliance.

   In the past decade, there have been significant advancements in the development of targeted therapies for chronic diseases. Researchers have made groundbreaking progress in devising targeted drugs and delivery systems to address the complexities and challenges posed by chronic conditions. This review aims to provide an overview of these research advances, showcasing the potential of targeted drugs in the treatment of chronic diseases and the potential benefits they offer to patients and healthcare systems alike.

   The role of targeted therapies in chronic respiratory diseases Targeted treatment of chronic obstructive pulmonary disease (COPD)

   Chronic Obstructive Pulmonary Disease (COPD) is a prevalent and severe chronic respiratory disease affecting millions of people worldwide, ranking as the third-leading cause of death globally. COPD, along with other respiratory conditions like acute respiratory distress syndrome, chronic pulmonary fibrosis, and lung cancer, is associated with long-term oxidative stress.

   Currently, therapeutic strategies for COPD mainly focus on alleviating symptoms, but targeted therapies hold promise as new treatment options for COPD patients and could serve as important adjuvant treatments. Researchers have developed new targeted drugs based on the pathogenesis of COPD, including cytokine inhibitors, chemokine receptor antagonists, phosphodiesterase 4 inhibitors, nuclear factor B (NF-B) inhibitors, and protease inhibitors.

   Lung administration of targeted therapies offers several advantages over oral administration. It allows for faster absorption rates, a concentrated distribution of metabolic enzymes in the lung, and lower rates of degradation of the active ingredient.

The effectiveness of drug deposition in the respiratory system is influenced by the particle diameter used for drug delivery. Studies have found that drug delivery systems producing a higher proportion of drug particles with a diameter between 1.0 and 3.0 micrometers result in better therapeutic effects, as more drugs settle in the alveoli and bronchioles.

To achieve this desired deposition pattern, researchers are exploring new drug delivery systems like liposomes, nanoparticles, solid lipid nanoparticles, microspheres, and microemulsions. These systems offer the potential to enhance the targeted delivery of drugs to the lungs and improve therapeutic outcomes for patients with COPD and other respiratory diseases. By capitalizing on these advanced drug delivery technologies, researchers aim to revolutionize COPD treatment and improve the quality of life for affected individuals.



Figure 3: Schematic diagram of particulate deposition in the human respiratory system

2. **Targeted drug delivery to specific tissues or organs:** The primary objective of a targeted drug delivery (TDD) system is to achieve prolonged, localized, and specific drug interactions with diseased tissues. In contrast to conventional drug delivery systems (DDSs), where drugs are typically absorbed across biological membranes, targeted release systems deliver drugs in a controlled dosage form.

   There are four key reasons for the need to adopt TDD over conventional DDSs, as depicted in Figure 4. First, conventional delivery methods may not adequately address the pharmacodynamic, pharmacokinetic, pharmaceutical, and pharmacotherapeutic aspects of drug performance. Targeting drugs to specific areas using optimized drug delivery methods becomes essential to enhance therapeutic effectiveness and reduce the toxicity associated with drugs having a narrow therapeutic index and high doses.

   To overcome the limitations and disadvantages of conventional DDSs, targeted drug delivery offers a solution. For instance, parenteral delivery can be highly invasive, oral administration is limited for certain drugs like protein- or peptide-derived ones, and topical creams and ointments are restricted to local effects. Targeting drugs to their sites of action at the right dosage and rate becomes crucial to achieve effective drug-target interactions with minimal side effects and maximum therapeutic benefits.

Targeted drug delivery also offers various promising advantages. It simplifies drug administration procedures, reduces the required drug quantity, thereby cutting down therapeutic costs, and allows for a significant increase in drug concentration at target sites without affecting non-targeted compartments negatively.

Overall, drug targeting through targeted drug delivery systems results in increased efficacy, modulated pharmacokinetics, controlled biodistribution, enhanced specificity of localization, reduced toxicity, lower dosages, and improved patient compliance. These benefits highlight the potential of TDD to revolutionize drug delivery, making it a crucial area of research and development in pharmaceutical science.



Figure 4: The need for targeted drug delivery

XII. BASIC PRINCIPLES AND APPLICATIONS OF TARGETED DRUG DELIVERY SYSTEMS

Drug targeting operates on the fundamental principle of delivering a high concentration of the drug to the specific targeted site while minimizing its concentration in non-targeted regions. This approach is crucial for optimizing the drug's therapeutic effects and reducing side effects resulting from interactions with multiple targets, higher doses, and non-target concentrations.

By focusing on drug targeting, unwanted interactions of the drug with bioenvironmental factors that could hinder its access to the intended target sites in the body are ameliorated, as illustrated in Figure 5. The process of drug targeting involves coordination among drug behavior, the selected targeting sites, and pharmaceutical carriers.

The "target" refers to the specific organ, cell, or group of cells that require treatment due to their chronic or acute condition, and this is the site where the drug will interact. The "carrier" is a specially designed molecule or system responsible for effectively transporting the loaded drug to the preselected target sites.

Ideally, a drug-targeting complex should possess several key attributes. It should be non-toxic, non-immunogenic, biochemically inert, biodegradable, biocompatible, and physically and chemically stable both in vivo and in vitro. Additionally, it should have a predictable and controllable pattern of drug release, be relatively simple to prepare with reproducibility, and be cost-effective. Furthermore, it should be easily and readily eliminated from the body and have minimal drug leakage during transit to the target site.

By meeting these criteria, a successful drug-targeting complex can significantly enhance the efficacy of drug therapy, minimize unwanted side effects, and pave the way for more effective and safer treatments for various medical conditions. As research in drug targeting advances, it holds the promise of revolutionizing drug delivery and improving patient outcomes across various diseases and conditions.



Figure 5: Principles of drug targeting.

XIII. CONTROLLED RELEASE OF DRUGS

Controlled drug delivery systems offer several advantages, such as maintaining drug levels within a desired therapeutic range, reducing the frequency of administrations, optimizing drug utilization, and enhancing patient compliance. These benefits can lead to more effective and convenient treatments for various medical conditions.

However, it is essential to consider the potential disadvantages of controlled drug delivery systems. Some of these drawbacks include the possible toxicity or non-biocompatibility of the materials used in the system, the generation of undesirable by-products during drug degradation, the need for surgical procedures to implant or remove the delivery system, the potential discomfort experienced by the patient due to the device, and the higher cost associated with controlled-release systems compared to conventional pharmaceutical formulations.

The ideal drug delivery system should meet several critical criteria. It should be made of inert and biocompatible materials, ensuring that it is safe for use in the human body. The system should also be mechanically strong to withstand the physiological environment it will be exposed to. Additionally, it should be comfortable for the patient, allowing for easy administration and removal. Achieving high drug loading capability is essential to ensure sufficient drug supply within the desired therapeutic range. Safety is paramount, and the system should prevent accidental release of drugs. Furthermore, simplicity in administration, fabrication, and sterilization is crucial to facilitate widespread use and ease of handling.

By carefully addressing these considerations and striking a balance between advantages and disadvantages, controlled drug delivery systems have the potential to revolutionize drug therapies and significantly improve patient outcomes across various medical conditions. Ongoing research and advancements in materials science and pharmaceutical technology will continue to contribute to the development of more effective, safe, and patient-friendly controlled drug delivery systems.

REFERENCE

[1] Danckwerts M, Fassihi A. Implantable controlled release drug delivery systems: A Review. Drug Dev Ind Pharm 1991;17:1465–502.
[2] Available from: http://www.pharmainfo.net/pppc06/implantable-drugdelivery-system. [Last accessed on November 1, 2010]
[3] Costantini LC, Kleppner SR, McDonough J, Azar MR, Patel R. Implantable technology for long-term delivery of nalmefene for the treatment of alcoholism Int J Pharm 2004;283:35-44
[4] Ranade V. Drug Delivery Systems Implants in drug delivery J Clin Pharm 1990;30:871-89
[5] Baker R. Controlled Release of Biologically Active Agents New York: John Wiley; 1987. p. 40–56
[6] Juni K., Ogata J., Nakano M., Ichihara T., Mori K., and Akagi M. Preparation and evaluation *in vitro* and *in vivo* of polylactic acid microspheres containing doxorubicin. Chem Pharm Bull 1985;33:313–8.
[7] Alekha KD, Greggrey CC. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods 1998;40:1–12.
[8] Higuchi T., Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 1961;50:874–879
[9] Lewis DH. Controlled release of bioactive agents from lactide and glycolide polymers. In: Chasin M., Langer R., editors Biodegradable Polymers as Drug Delivery Systems New York: Marcel Dekker; 190. p. 1–41
[10] Wood DA. Biodegradable drug delivery systems Int J Pharm 1980;7:1–18.
[11] Zaheer S., Lehman J., and Stevenson G. Capsular contracture around silicone implants: The role of intraluminal antibiotics Plast Reconstr Surg. 1982;69:809–12.
[12] Langer R. Implantable controlled release systems In: Ihler GM, editor. Methods of Drug Delivery New York: Pergamon Press; 1986. p. 121–37
[13] Graham, NB. Polymeric inserts and implants for the controlled release of drugs Br Polymer J 1978;10:260–6.
[14] Wang X, Chen T, Yang Z, and Wang W. Study on the structural optimum design of implantable drug delivery microsystems Simultaneous Modelling Practise Theory 2007;15:47–56.

[15] Sershen1 S, West J. Implantable, polymeric systems for modulated drug delivery Adv Drug Deliv Rev 2002;54:1225–35
[16] 16. Kimura H, Ogura Y, Hashizoe M, Nishiwaki H, Honda Y, and Ikada Y a new vitreal drug delivery system using an implantable biodegradable polymeric device. Invest Ophthalmol Vis Sci 1994;35:2815–9.
[17] Brown LR, Wei CL, and Langer R. *In vivo* and *in vitro* release of macromolecules form polymeric drug delivery systems. J Pharm Sci 1983;72:1181–5.
[18] Rhine W, Hsieh DS, and Langer R. Polymers for sustained macromolecule release: Procedures to fabricate reproducible delivery systems and control release kinetics J Pharm Sci 1980;69:265-70.
[19] Barrera D, Zylstra E, Lansbury PT, Langer R. Synthesis and RGD peptide modification of a new biodegradable copolymer: Poly(lactic acid-colysine). J Am Chem Soc 1993;115:11010-1
[20] 20. Dagani R. Biodegradable copolymer eyed as tissue matrix Chem Eng News 1993;22:5-8.
[21] Cao L, Mentell S, and Polla D. Design and simulation of an implantable medical drug delivery system using microelectromechanical systems technology. Sens Actuators A Phys 2001;94:117-25
[22] Renard E. Implantable closed-loop glucose sensing and insulin delivery: The future for insulin pump therapy Curr Opin Pharmacol 2002;2:708–16.
[23] Blackshear PJ, Rhode TH. Artificial devices for insulin infusion in the treatment of patients with diabetes mellitus. In: Burk SD, editor. Controlled Drug Delivery, Clinical Applications, Vol. 2, Boca Raton, FL: CRC Press; 1983, p. 11.
[24] Dash AK, Suryanarayanan R. An implantable dosage form for the treatment of bone infections Pharm Res 1992;9:993-1002.
[25] Sefton MV. Implantable pumps CRC Crit Rev Bioeng 1987;14:201–40.

